Proteomic approaches in neuroblastoma: a complementary clinical platform for the future

References

• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet369(9579), 2106–2120 (2007).
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer3(3), 203–216 (2003).
   PubMed Web of Science ®Google Scholar
• Shimada H, Umehara S, Monobe Y et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer92(9), 2451–2461 (2001).
   PubMed Web of Science ®Google Scholar
• Hsu WM, Lee H, Juan HF et al. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin. Cancer Res.14(19), 6237–6245 (2008).
   PubMed Web of Science ®Google Scholar
• Zanini C, Pulerà F, Carta F et al. Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing’s sarcoma. Virchows Arch.452(2), 157–167 (2008).
   PubMed Web of Science ®Google Scholar
• Cimmino F, Spano D, Capasso M et al. Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line. J. Proteome Res.6(7), 2550–2564 (2007).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Hickey RJ, Malkas LH. Isolation and characterization of a DNA synthesome from a neuroblastoma cell line. J. Pediatr. Surg.40(7), 1070–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Grosfeld JL, Hickey RJ, Malkas LH. Structural analysis of the human neuroblastoma DNA replication complex: insights into faulty proliferation. J. Pediatr. Surg.41(1), 266–270 (2006).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Eppstein AC, Hoelz DJ et al. Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling. J. Surg Res.134(1), 61–67 (2006).
   PubMed Web of Science ®Google Scholar
• Eppstein AC, Sandoval JA, Klein PJ et al. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. J. Pediatr. Surg.41(1), 252–259 (2006).
   PubMed Web of Science ®Google Scholar
• Izbicka E, Campos D, Marty J, Carrizales G, Mangold G, Tolcher A. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res.26(3A), 1983–1988 (2006).
   PubMed Web of Science ®Google Scholar
• Urbani A, Poland J, Bernardini S et al. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics5(3), 796–804 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar HR, Zhong X, Hoelz DJ et al. Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr. Surg. Int.24(11), 1229–1234 (2008).
   PubMed Web of Science ®Google Scholar
• Turner KE, Kumar HR, Hoelz DJ et al. Proteomic analysis of neuroblastoma microenvironment: effect of the host–tumor interaction on disease progression. J. Surg. Res. DOI:10.1016/j.jss.2009.02.019 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Campostrini N, Pascali J, Hamdan M et al. Proteomic analysis of an orthotopic neuroblastoma xenograft animal model. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.808(2), 279–286 (2004).
   PubMed Web of Science ®Google Scholar
• Novotny NM, Grosfeld JL, Turner KE et al. Oxidative status in neuroblastoma: a source of stress? J. Pediatr. Surg.43(2), 330–334 (2008).
   PubMed Web of Science ®Google Scholar
• Baek YM, Hwang HJ, Kim SW et al. A comparative proteomic analysis for capsaicin-induced apoptosis between human hepatocarcinoma (HepG2) and human neuroblastoma (SK-N-SH) cells. Proteomics8(22), 4748–4767 (2008).
   PubMed Web of Science ®Google Scholar
• Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α 1-antichymotrpsin before diagnosis of prostate cancer. Lancet344(8937), 1594–1598 (1994).
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5(11), 845–856 (2005).
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur. J. Cancer39(13), 1899–1903 (2003).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Dobrolecki LE, Huang J, Grosfeld JL, Hickey RJ, Malkas LH. Neuroblastoma detection using serum proteomic profiling: a novel mining technique for cancer? J. Pediatr. Surg.41(4), 639–646 (2006).
   PubMed Web of Science ®Google Scholar
• Combaret V, Bergeron C, Bréjon S et al. Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett.228(1–2), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• He QY, Zhu R, Ren Y, Tam PK, Chiu JF. Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology. J. Cell. Biochem.95(1), 165–72 (2005).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Turner KE, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH. Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. J. Surg. Res.142(2), 268–274 (2007).
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Hoelz DJ, Woodruff HA et al. Novel peptides secreted from human neuroblastoma: useful clinical tools? J. Pediatr. Surg.41(1), 245–251 (2006).
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J. Clin. Oncol.27(2), 289–297 (2009).
   PubMed Web of Science ®Google Scholar
• Maris JM, Mosse YP, Bradfield JP et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med.358(24), 2585–2593 (2008).
   PubMed Web of Science ®Google Scholar
• Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med.353(21), 2243–2253 (2005).
   PubMed Web of Science ®Google Scholar
• Caron H, van Sluis P, de Kraker J et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med.334(4), 225–230 (1996).
   PubMed Web of Science ®Google Scholar
• Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med.340(25), 1954–1961 (1999).
   PubMed Web of Science ®Google Scholar
• Barrett T, Troup DB, Wilhite SE et al. NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res.37, D885–D890 (2009).
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia9(2), 166–180 (2007).
   PubMed Web of Science ®Google Scholar
• Oberthuer A, Berthold F, Warnat P et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol.24(31), 5070–5078 (2006).
   PubMed Web of Science ®Google Scholar
• Schramm A, Vandesompele J, Schulte JH et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin. Cancer Res.13(5), 1459–1465 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res.67(3), 976–983 (2007).
   PubMed Web of Science ®Google Scholar
• Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene26(34), 5017–5022 (2007).
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature447(7148), 1130–1134 (2007).
   PubMed Web of Science ®Google Scholar
• Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA104(39), 15472–15477 (2007).
   PubMed Web of Science ®Google Scholar
• Schulte JH, Horn S, Otto T et al. MYCN regulates oncogenic microRNAs in neuroblastoma. Int. J. Cancer122(3), 699–704 (2008).
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature435(7043), 828–833 (2005).
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature435(7043), 839–843 (2005).
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature438(7068), 685–689 (2005).
   PubMed Web of Science ®Google Scholar
• Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Therapy13(6), 496–502 (2006).
   PubMed Web of Science ®Google Scholar
• German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics1(1), 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diag.4(2), 89–99 (2004).
   Web of Science ®Google Scholar
• Lindskog M, Kogner P, Ponthan F et al. Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (1H MRS). Br. J. Cancer88(3), 478–485 (2003).
   PubMed Web of Science ®Google Scholar
• Lindskog M, Spenger C, Jarvet J, Gräslund A, Kogner P. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J. Natl. Cancer Inst.96(19), 1457–1466 (2004).
   PubMedGoogle Scholar
• Wishart DS, Tzur D, Knox C et al. HMDB: the human metabolome database. Nucleic Acids Res.35, D521–D526 (2007).
   PubMed Web of Science ®Google Scholar
• Schmelzer K, Fahy E, Subramaniam S, Dennis EA. The lipid maps initiative in lipidomics. Methods Enzymol.432, 171–183 (2007).
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science295(5560), 1662–1664 (2002).
   PubMed Web of Science ®Google Scholar
• Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet.2, 343–372 (2001).
   PubMed Web of Science ®Google Scholar
• van der Greef J, Martin S, Juhasz P et al. The art and practice of systems biology in medicine: mapping patterns of relationships. J.Proteome. Res.6(4), 1540–1559 (2007).
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B.57(1), 289–300 (1995).
   Web of Science ®Google Scholar
• Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA98(9), 5116–5121 (2001).
   PubMed Web of Science ®Google Scholar
• Steuer R, Kurths J, Fiehn O, Weckwerth W. Interpreting correlations in metabolomic networks. Biochem. Soc. Trans.31(Pt 6), 1476–1478 (2003).
   PubMed Web of Science ®Google Scholar
• Steuer R, Kurths J, Fiehn O, Weckwerth W. Observing and interpreting correlations in metabolomic networks. Bioinformatics19(8), 1019–1026 (2003).
   PubMed Web of Science ®Google Scholar
• Li DJ, Deng G, Xiao ZQ et al. Indentificating 14–3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett.279(1), 65–73 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Huang WG, Chen ZC et al. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. J. roteome Res.7(6), 2415–2426 (2008).
   PubMed Web of Science ®Google Scholar
• Banks RE, Stanley AJ, Cairns DA et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem.51(9), 1637–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Rai AJ, Gelfand CA, Haywood BC et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics5(13), 3262–3277 (2005).
   PubMed Web of Science ®Google Scholar
• Omenn GS. Strategies for plasma proteomic profiling of cancers. Proteomics6(20), 5662–5673 (2006).
   PubMed Web of Science ®Google Scholar
• States DJ, Omenn GS, Blackwell TW et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol.24(3), 333–338 (2006).
   PubMed Web of Science ®Google Scholar
• Chernokalskaya E, Gutierrez S, Pitt AM, Leonard JT. Ultrafiltration for proteomic sample preparation. Electrophoresis25(15), 2461–2468 (2004).
   PubMed Web of Science ®Google Scholar
• Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics2(10), 1096–1103 (2003).
   PubMed Web of Science ®Google Scholar
• Chertov O, Biragyn A, Kwak LW et al. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. Proteomics4(4), 1195–1203 (2004).
   PubMed Web of Science ®Google Scholar
• Marshall J, Jankowski A, Furesz S et al. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J. Proteome Res.3(3), 364–382 (2004).
   PubMed Web of Science ®Google Scholar
• Callesen AK, Madsen JS, Vach W, Kruse TA, Mogensen O, Jensen ON. Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics9(6), 1428–1441 (2009).
   PubMed Web of Science ®Google Scholar
• Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics1(5), 376–386 (2002).
   PubMed Web of Science ®Google Scholar
• Wiese S, Reidegeld KA, Meyer HE, Warscheid B. Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics7(3), 340–350 (2007).
   PubMed Web of Science ®Google Scholar